Laser Photonics Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Laser Photonics Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $721.2K | Jun 24, 2025 |
| FY2023 | Dec 31, 2023 | $3.94M | Apr 19, 2024 |
| FY2023 | Dec 31, 2022 | $3.89M | Apr 19, 2024 |
| FY2022 | Dec 31, 2021 | $4.19M | Nov 17, 2023 |
| FY2020 | Dec 31, 2020 | $809.3K | Mar 26, 2021 |
| FY2020 | Sep 30, 2020 | $607.7K | Mar 26, 2021 |
| FY2020 | Jun 30, 2020 | $559.9K | Mar 26, 2021 |
| FY2020 | Mar 31, 2020 | $177.9K | Mar 26, 2021 |
| FY2020 | Dec 31, 2019 | $0 | Mar 26, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $3.37M | Jun 24, 2025 |
| FY2024 | Dec 31, 2023 | $3.94M | Jun 24, 2025 |
| FY2023 | Dec 31, 2022 | $3.89M | Sep 12, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.48M | Jun 24, 2025 |
| FY2024 | Dec 31, 2023 | $2.90M | Jun 24, 2025 |
| FY2023 | Dec 31, 2022 | $1.95M | Sep 12, 2024 |
| FY2022 | Dec 31, 2021 | $2.13M | Nov 17, 2023 |
| FY2020 | Dec 31, 2020 | $392.1K | Mar 26, 2021 |
| FY2020 | Sep 30, 2020 | $346.7K | Mar 26, 2021 |
| FY2020 | Jun 30, 2020 | $345.6K | Mar 26, 2021 |
| FY2020 | Mar 31, 2020 | $120.6K | Mar 26, 2021 |
| FY2020 | Dec 31, 2019 | $0 | Mar 26, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($2.52M) | Jun 24, 2025 |
| FY2024 | Dec 31, 2023 | ($3.32M) | Jun 24, 2025 |
| FY2023 | Dec 31, 2022 | ($2.09M) | Sep 12, 2024 |
| FY2021 | Dec 31, 2021 | $42.2K | Apr 1, 2022 |
| FY2021 | Sep 30, 2021 | $155.2K | Apr 1, 2022 |
| FY2021 | Jun 30, 2021 | $265.5K | Apr 1, 2022 |
| FY2021 | Mar 31, 2021 | $123.3K | Apr 1, 2022 |
| FY2020 | Dec 31, 2020 | $9.5K | Mar 26, 2021 |
| FY2021 | Sep 30, 2020 | $16.5K | Apr 1, 2022 |
| FY2021 | Jun 30, 2020 | $123.3K | Apr 1, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($6.46M) | Jun 24, 2025 |
| FY2024 | Dec 31, 2023 | ($3.35M) | Jun 24, 2025 |
| FY2023 | Dec 31, 2022 | ($2.07M) | Sep 12, 2024 |
| FY2022 | Dec 31, 2021 | $611.1K | Nov 17, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $261.9K | Jun 24, 2025 |
| FY2024 | Dec 31, 2023 | $202.3K | Jun 24, 2025 |
| FY2023 | Dec 31, 2022 | $100.8K | Sep 12, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($9.14M) | Jun 24, 2025 |
| FY2024 | Dec 31, 2023 | ($5.47M) | Jun 24, 2025 |
| FY2023 | Dec 31, 2022 | ($63.4K) | Sep 12, 2024 |
| FY2022 | Dec 31, 2021 | $1.38M | Nov 17, 2023 |
| FY2021 | Dec 31, 2020 | ($1.53M) | Aug 26, 2022 |
| FY2020 | Dec 31, 2019 | ($505.5K) | Mar 26, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $76.7K | Jun 24, 2025 |
| FY2023 | Dec 31, 2022 | $689.3K | Sep 12, 2024 |
| FY2022 | Dec 31, 2021 | $2.8K | Nov 17, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $17.15M | Jun 24, 2025 |
| FY2024 | Dec 31, 2023 | $15.12M | Jun 24, 2025 |
| FY2023 | Dec 31, 2022 | $18.58M | Sep 12, 2024 |
| FY2022 | Dec 31, 2021 | $6.86M | Nov 17, 2023 |
| FY2021 | Dec 31, 2020 | $7.48M | Aug 26, 2022 |
| FY2020 | Dec 31, 2019 | $495.2K | Mar 26, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $6.94M | Jun 24, 2025 |
| FY2024 | Dec 31, 2023 | $1.19M | Jun 24, 2025 |
| FY2023 | Dec 31, 2022 | $1.45M | Sep 12, 2024 |
| FY2022 | Dec 31, 2021 | $1.30M | Nov 17, 2023 |
| FY2021 | Dec 31, 2020 | $2.20M | Aug 26, 2022 |
| FY2020 | Dec 31, 2019 | $5.3K | Mar 26, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $10.21M | Jun 24, 2025 |
| FY2024 | Dec 31, 2023 | $13.93M | Jun 24, 2025 |
| FY2024 | Dec 31, 2022 | $17.13M | Jun 24, 2025 |
| FY2023 | Dec 31, 2021 | $5.47M | Sep 12, 2024 |
| FY2021 | Sep 30, 2021 | $5.83M | Apr 1, 2022 |
| FY2021 | Jun 30, 2021 | $5.68M | Apr 1, 2022 |
| FY2021 | Mar 31, 2021 | $5.41M | Apr 1, 2022 |
| FY2021 | Jan 1, 2021 | $5.29M | Apr 1, 2022 |
| FY2022 | Dec 31, 2020 | $5.29M | Nov 17, 2023 |
| FY2021 | Sep 30, 2020 | $647.8K | Apr 1, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($7.75M) | Jun 24, 2025 |
| FY2024 | Dec 31, 2023 | ($5.24M) | Jun 24, 2025 |
| FY2023 | Dec 31, 2022 | ($1.92M) | Sep 12, 2024 |
| FY2022 | Dec 31, 2021 | $269.3K | Nov 17, 2023 |
| FY2021 | Dec 31, 2020 | ($5.0K) | Aug 26, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Mar 26, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $533.9K | Jun 24, 2025 |
| FY2024 | Dec 31, 2023 | $6.20M | Jun 24, 2025 |
| FY2023 | Dec 31, 2022 | $12.18M | Sep 12, 2024 |
| FY2023 | Dec 31, 2021 | $615.7K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $326.7K | Aug 26, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Mar 26, 2021 |
| FY2020 | Dec 31, 2018 | $0 | Mar 26, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Jun 24, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Jun 24, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Sep 12, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Nov 17, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Jun 24, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Jun 24, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Sep 12, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Nov 17, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Aug 26, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 14.26M | Jun 24, 2025 |
| FY2024 | Dec 31, 2023 | 9.23M | Jun 24, 2025 |
| FY2023 | Dec 31, 2022 | 7.88M | Sep 12, 2024 |
| FY2022 | Dec 31, 2021 | 4.88M | Nov 17, 2023 |
| FY2021 | Dec 31, 2020 | 4.88M | Aug 26, 2022 |